References
- Corbett J A, McDaniel M L. Does nitric oxide mediate autoimmune destruction of β-cells? Possible therapeutic interventions in IDDM. Diabetes 1992; 41: 897–903
- Kolb H, Kolb-Bachofen V. Nitric oxide: a pathogenetic factor in autoimmunity. Immunol Today 1992; 13: 157–160
- Southern C, Schulster D, Green I C. Inhibition of insulin secretion by interleukin-1 β and tumour necrosis factor-a via an L-arginine-dependent nitric oxide generating mechanism. FEBS Lett 1990; 276: 42–44
- Welsh N, Eizirik D L, Bendtzen K, Sandler S. Interleukin-1β-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase. Endocrinology 1991; 129: 3167–3173
- Sandler S, Eizirik D L, Svensson C, Strandell E, Welsh M, Welsh N. Biochemical and molecular actions of interleukin-1 on pancreatic β-cells. Autoimmunity 1991; 10: 241–253
- Corbett J A, Lancaster J R, Jr., Sweetland M A, McDaniel M L. Interleukin-lβ-induced formation of EPR-detectable iron-nitrosyl complexes in islets of Langerhans. Role of nitric oxide in interleukin-lβ-induced inhibition of insulin secretion. J Biol Chem 1991; 266: 21351–21354
- Bergmann L, Kröncke K-D, Suschek C, Kolb H, Kolb-Bachofen V. Cytotoxic action of IL-1β against pancreatic islets is mediated via nitric oxide formation and is inhibited by NG-monomethyl-L-aginine. FEBS Lett 1992; 299: 103–106
- Lukic M L, Stosic-Grujicic S, Ostojic N, Chan W L, Liew F Y. Inhibition of nitric oxide generation affects the induction of diabetes by streptozocin in mice. Biochem Biophys Res Commun 1991; 178: 913–920
- Kolb H, Kiesel U, Kroncke K-D, Kolb-Bachofen V. Suppression of low dose streptozotocin induced diabetes in mice by administration of a nitric oxide synthase inhibitor. Life Sci 1991; 49: PL-213–PL-217
- Like A A, Rossini A A. Streptozotocin-induced pancreatic insulitis: a new model of diabetes mellitus. Science 1976; 193: 415–417
- Corbett J A, Tilton R G, Chang K, Hasan K S, Ido Y, Wang J L, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetes vascular dysfunction. Diabetes 1992; 41: 552–556
- Sandler S, Andersson A. Modulation of streptozotocin-induced insulitis and hyperglycemia in the mouse. Acta Path Microbiol Immunol Scand Sect [A] 1985; 412: 225–230
- Jansson L, Sandler S. The influence of cyclosporin A on the vascular permeability of the pancreatic islets and on diabetes induced by low doses of streptozotocin in the mouse. Virchows Arch A [Pathol Anat] 1988; 412: 225–230
- Sandler S, Andersson A, Hellerström C. Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis, and oxidative metabolism of rat pancreatic islets. Endocrinology 1987; 121: 1424–1431
- Andersson A, Sandler S. Viability tests of cryopreserved endocrine pancreatic cells. Cryobiology 1983; 20: 161–168
- Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced atrerial wall protein cross-linking. Science 1986; 232: 1629–1632
- Eizirik D L, Cagliero E, Björklund A, Welsh N. Interleukin-1β induces the expression of an isoform of nitric oxide synthase in insulin-producing cells, which is similar to that observed in activated macrophages. FEBS Lett 1992; 308: 249–252
- Kolb-Bachofen V, Epstein S, Kiesel U, Kolb H. Low-dose streptozotocin-induced diabetes in mice. Electron microscopy reveals single-cell insulitis before diabetes onset. Diabetes 1988; 37: 21–27
- Zähner D, Malaisse W J. Effects of advanced glycation products and aminoguanidine upon insulin release. Diab Nutr Metab 1992; 5: 43–46